Login to Your Account

Vaccine developer Cansino pads coffers with $30M VC round

By Shannon Ellis
Staff Writer

Tuesday, November 3, 2015

SHANGHAI – Tianjin Cansino Inc., the company behind China's phase II Ebola vaccine, has received a $30 million investment from well-respected health care venture firms Qiming Venture Partners and Lilly Asia Ventures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription